Market Cap 10.95M
Revenue (ttm) 0.00
Net Income (ttm) -16.75M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 8,800
Avg Vol 175,962
Day's Range N/A - N/A
Shares Out 834,000.00
Stochastic %K 34%
Beta 1.50
Analysts Strong Buy
Price Target $10.00

Company Profile

TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and t...

Industry: Biotechnology
Sector: Healthcare
Phone: 857-837-3099
Address:
6 Liberty Square, Suite 2382, Boston, United States
AppleLuvr
AppleLuvr Oct. 25 at 6:53 PM
$RNAZ Love seeing traders like @Invinc1ble spotting trends early. Respect the grind. 💪 If you're active trader I recommend a follow
0 · Reply
invinc1ble
invinc1ble Oct. 25 at 3:54 PM
$RNAZ I went in early and left with 200% - Alerts are forever free
0 · Reply
Itinerant
Itinerant Oct. 24 at 11:37 PM
$RNAZ The market is still digesting the implication of CK's acquisition of RNAZ. I am happy with it. Our risk has been greater reduced. Soon enough the market will get enthusiastic about the situation. JMo
0 · Reply
tradingwithrick
tradingwithrick Oct. 24 at 1:28 AM
$RNAZ man this stock I shit! When will it explode up ⬆️??
0 · Reply
MasterNumber11
MasterNumber11 Oct. 23 at 11:49 PM
$RNAZ Let's get it
0 · Reply
Itinerant
Itinerant Oct. 23 at 8:40 PM
$RNAZ I think that it is an important question when and how will the company finance the P3 of the melanoma vaccine. I have no particular idea at the moment, but maybe they will tell us something about this in the earnings report, maybe not. I imagine they must have an FDA meeting to affirm the P3 design.
0 · Reply
ShadowSnake
ShadowSnake Oct. 23 at 4:52 PM
$RNAZ go to $30!!!
1 · Reply
dishenghk
dishenghk Oct. 23 at 4:27 PM
$RNAZ My friends, I think the stock price should be sideways for a long time. Because the next big news is the start of the second phase of the experiment, but it may have to wait until 2026. Fortunately, we have obtained cvr, so we can invest the funds from rnaz to other fields.
1 · Reply
Scrubinski
Scrubinski Oct. 23 at 1:57 PM
$RNAZ My CVRs showed up, so that is nice. I'm thinking this is going to settle around $10, so I trimmed a bit and then will probably buy an amount that I don't mind sitting on for several years without expecting a pop for a while. Wish the bump on the news was better as I'm still minus in the long run, but at least it was fun for a while.
1 · Reply
Vedran1
Vedran1 Oct. 23 at 12:57 PM
$RNAZ We might be witnessing the "post CVR record date" bubble burst. RNAZ will reset to new price levels whenever a new sufficient support emerges for whatever reason. I am already looking beyond 7 years CVR era and will be patiently positioning - before it comes.
2 · Reply
Latest News on RNAZ
TransCode Therapeutics Announces 1-for-28 Reverse Stock Split

May 2, 2025, 4:10 PM EDT - 6 months ago

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split


TransCode Therapeutics Open Letter to Shareholders

May 13, 2024, 8:30 AM EDT - 1 year ago

TransCode Therapeutics Open Letter to Shareholders


TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

Jan 11, 2024, 8:00 AM EST - 1 year ago

TransCode Therapeutics Announces 1-for-40 Reverse Stock Split


TransCode Therapeutics Withdraws Public Offering

Oct 30, 2023, 4:33 PM EDT - 2 years ago

TransCode Therapeutics Withdraws Public Offering


AppleLuvr
AppleLuvr Oct. 25 at 6:53 PM
$RNAZ Love seeing traders like @Invinc1ble spotting trends early. Respect the grind. 💪 If you're active trader I recommend a follow
0 · Reply
invinc1ble
invinc1ble Oct. 25 at 3:54 PM
$RNAZ I went in early and left with 200% - Alerts are forever free
0 · Reply
Itinerant
Itinerant Oct. 24 at 11:37 PM
$RNAZ The market is still digesting the implication of CK's acquisition of RNAZ. I am happy with it. Our risk has been greater reduced. Soon enough the market will get enthusiastic about the situation. JMo
0 · Reply
tradingwithrick
tradingwithrick Oct. 24 at 1:28 AM
$RNAZ man this stock I shit! When will it explode up ⬆️??
0 · Reply
MasterNumber11
MasterNumber11 Oct. 23 at 11:49 PM
$RNAZ Let's get it
0 · Reply
Itinerant
Itinerant Oct. 23 at 8:40 PM
$RNAZ I think that it is an important question when and how will the company finance the P3 of the melanoma vaccine. I have no particular idea at the moment, but maybe they will tell us something about this in the earnings report, maybe not. I imagine they must have an FDA meeting to affirm the P3 design.
0 · Reply
ShadowSnake
ShadowSnake Oct. 23 at 4:52 PM
$RNAZ go to $30!!!
1 · Reply
dishenghk
dishenghk Oct. 23 at 4:27 PM
$RNAZ My friends, I think the stock price should be sideways for a long time. Because the next big news is the start of the second phase of the experiment, but it may have to wait until 2026. Fortunately, we have obtained cvr, so we can invest the funds from rnaz to other fields.
1 · Reply
Scrubinski
Scrubinski Oct. 23 at 1:57 PM
$RNAZ My CVRs showed up, so that is nice. I'm thinking this is going to settle around $10, so I trimmed a bit and then will probably buy an amount that I don't mind sitting on for several years without expecting a pop for a while. Wish the bump on the news was better as I'm still minus in the long run, but at least it was fun for a while.
1 · Reply
Vedran1
Vedran1 Oct. 23 at 12:57 PM
$RNAZ We might be witnessing the "post CVR record date" bubble burst. RNAZ will reset to new price levels whenever a new sufficient support emerges for whatever reason. I am already looking beyond 7 years CVR era and will be patiently positioning - before it comes.
2 · Reply
ShadowSnake
ShadowSnake Oct. 22 at 9:55 PM
$RNAZ the CRV in my account is blank… any idea what they represent?!
1 · Reply
ShadowSnake
ShadowSnake Oct. 22 at 6:16 PM
$RNAZ WTH happened man!?
0 · Reply
phantomtrader75
phantomtrader75 Oct. 22 at 4:29 PM
$RNAZ OMG $30 seems like a dream.
0 · Reply
ioiioiioiioi
ioiioiioiioi Oct. 22 at 3:41 PM
$RNAZ Selling pressure is so strong.. How long do we have to wait again? Why is it so undervalued..? It’s too much.. Phase 2 will probably start next year.. Is there no other trigger in the meantime?
1 · Reply
Hovius
Hovius Oct. 22 at 3:07 PM
$RNAZ Brutal day… back to $10-$12. Wonder how presentation went.
0 · Reply
ShadowSnake
ShadowSnake Oct. 22 at 11:58 AM
$RNAZ I received my 893CRV today.. it’s blank but they were distributed it seems
0 · Reply
dishenghk
dishenghk Oct. 22 at 10:37 AM
$RNAZ I also received my CVR information from the ibkr, and it seems that Monday's purchase is valid as well. I hope ttx-mc138 can be licensed to other major pharmaceutical companies for a fee as soon as possible, so that we can receive payment
1 · Reply
Vedran1
Vedran1 Oct. 22 at 1:53 AM
$RNAZ Anyone here considering more we talk at this time about CVR than RNAZ we might be actually hurting RNAZ? Or it is just me. Anyways, I will keep adding as new cash keeps coming to my drained RNAZ accounts.
1 · Reply
Vedran1
Vedran1 Oct. 22 at 1:42 AM
$RNAZ Schwab has listed CVR under account positions in my both accounts: IRA and regular account.
2 · Reply
testing1234
testing1234 Oct. 22 at 1:28 AM
$RNAZ so why is it not tradable on RH? Can we still sell our shares tomorrow?
1 · Reply
Scrubinski
Scrubinski Oct. 21 at 10:51 PM
$RNAZ Does anybody know how we can be certain that we are participating in the CVR? Should we be expecting a letter in the mail or something?
1 · Reply
deepeeenn
deepeeenn Oct. 21 at 8:56 PM
$RNAZ Genuine question, there is a likelihood at some point, because the share make up of this stock (tiny float and reasonably priced) that on release of "good" news that doesn't happen to contribute monetarily to the CVR, that this could again see a surge. Is the company relying on an event like this to shake loose short term investors? You would effectively lose your CVR rights and new shareholders would not acquire them. But then, when a CVR event does occur, the amount they would would dispense would go to a lesser population of investors. Making the CVR more valuable, no?
1 · Reply